Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

83.50 -0.03 (-0.04%)
Streaming Delayed Price Updated: 10:54 AM EDT, Jul 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,069,391
Open 83.52
Bid (Size) 83.49 (16,400)
Ask (Size) 83.50 (9,400)
Prev. Close 83.53
Today's Range 83.47 - 83.57
52wk Range 25.83 - 83.63
Shares Outstanding 54,026,103
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis... 
Via MarketBeat
News headline image
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. ↗
This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate. 
Via The Motley Fool

Performance

YTD
+78.7%
+78.7%
1 Month
+149.4%
+149.4%
3 Month
+117.4%
+117.4%
6 Month
+81.7%
+81.7%
1 Year
+187.3%
+187.3%

More News

Read More
News headline image
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. ↗
Via The Motley Fool
Topics Intellectual Property
Crinetics Pharmaceuticals (NASDAQ:CRNX) Beats Q1 Expectations on Strong PALSONIFY Launch, Stock Slips After Hours ↗
Via Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Most active stocks in Tuesday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
Top stock movements in today's session. ↗
Via Chartmill
News headline image
CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
The market is filled with gapping stocks in Tuesday's session. ↗
Via Chartmill
Discover the top movers in Tuesday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
Monday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Vertex to Acquire Crinetics Pharmaceuticals
From Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.
Via Business Wire
News headline image
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Crinetics (CRNX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Crinetics Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Crinetics Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Crinetics Pharmaceuticals, Inc. - Common Stock trade on?
Crinetics Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock is CRNX on the Nasdaq Stock Market
What is the current price of Crinetics Pharmaceuticals, Inc. - Common Stock?
The current price of Crinetics Pharmaceuticals, Inc. - Common Stock is 83.50
When was Crinetics Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Crinetics Pharmaceuticals, Inc. - Common Stock was at 07/08/26 10:54 AM ET
What is the market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock is 4.51B
How many shares of Crinetics Pharmaceuticals, Inc. - Common Stock are outstanding?
Crinetics Pharmaceuticals, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.